| 0.6099 -0 (-0.02%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.83 | 1-year : | 0.93 |
| Resists | First : | 0.71 | Second : | 0.8 |
| Pivot price | 0.62 |
|||
| Supports | First : | 0.58 | Second : | 0.48 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.64 |
| MA(100) : | 0.74 |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25 |
D(3) : | 24.8 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 1.72 | Low : | 0.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LAB ] has closed above bottom band by 26.5%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.63 - 0.63 | 0.63 - 0.63 |
| Low: | 0.6 - 0.6 | 0.6 - 0.6 |
| Close: | 0.6 - 0.61 | 0.61 - 0.61 |
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Fri, 30 Oct 2026
No resale proceeds will go to Standard BioTools (LAB) from Treeline holders’ merger shares. - Stock Titan
Sat, 24 Oct 2026
Standard BioTools Inc. Estimates – NASDAQ:LAB - TradingView
Thu, 22 Oct 2026
STANDARD BIOTOOLS INC. SEC Filing (Oct 22, 2026) - Stock Titan
Mon, 05 Oct 2026
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED - GlobeNewswire
Wed, 30 Sep 2026
Standard BioTools Provides Update on Sale of Mass Cytometry Business - Yahoo Finance
Fri, 14 Aug 2026
LAB: Standard BioTools Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 395 (M) |
| Shares Float | 185 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 75.2 (%) |
| Shares Short | 2,520 (K) |
| Shares Short P.Month | 2,980 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 100.3 % |
| Operating Margin | -39 % |
| Return on Assets (ttm) | -6.7 % |
| Return on Equity (ttm) | -11.2 % |
| Qtrly Rev. Growth | -7.6 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | 177 (M) |
| PE Ratio | -4.71 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 2.85 |
| Price to Cash Flow | -3.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|